Johnson & Johnson (JNJ) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Johnson & Johnson reported revenue of $94.19B, up 6.0% from $88.82B the year before. Net income was $26.80B (a 28.5% net margin), or $11.03 per diluted share. Gross margin was 67.9% and operating margin was 42.6%. Operating activities generated $24.53B of cash, leaving $19.70B of free cash flow. At fiscal year end, Johnson & Johnson held $199.21B in total assets against $117.67B in total liabilities, including $19.71B of cash and equivalents.
Open the full interactive Johnson & Johnson financials → Quarterly statements, key ratios, valuation history and price charts.
Johnson & Johnson Key Stats
| Share Price | $248.61 |
|---|---|
| Market Cap | $606.63B |
| P/E Ratio | 22.5 |
| Revenue YoY Growth | +6.0% |
| 52-Week Range | $181.90 – $278.43 |
| Shares Outstanding | 2.41 billion (basic, 2026 Q2) |
Johnson & Johnson Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $82.58B | $93.78B | $94.94B | $85.16B | $88.82B | $94.19B |
| Cost of Goods Sold | $28.43B | $29.86B | $31.09B | $26.55B | $27.47B | $30.26B |
| Gross Profit | $54.16B | $63.92B | $63.85B | $58.61B | $61.35B | $63.94B |
| Operating Income | $32.07B | $39.26B | $39.09B | $36.61B | $36.64B | $40.15B |
| Pre-Tax Income | $16.50B | $22.78B | $21.73B | $15.06B | $16.69B | $32.58B |
| Income Tax | $1.78B | $1.90B | $3.78B | $1.74B | $2.62B | $5.78B |
| Net Income | $14.71B | $20.88B | $17.94B | $35.15B | $14.07B | $26.80B |
| Diluted EPS | $5.51 | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
Johnson & Johnson Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $23.99B | $24.56B | $24.06B | $25.31B |
| Net Income | $5.15B | $5.12B | $5.24B | $5.53B |
| Diluted EPS | $2.12 | $2.11 | $2.14 | $2.27 |
Johnson & Johnson Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.98B | $14.49B | $14.13B | $21.86B | $24.11B | $19.71B |
| Current Assets | $51.24B | $60.98B | $55.29B | $53.49B | $55.89B | $55.62B |
| Total Assets | $174.89B | $182.02B | $187.38B | $167.56B | $180.10B | $199.21B |
| Current Liabilities | $42.49B | $45.23B | $55.80B | $46.28B | $50.32B | $54.13B |
| Total Long-Term Debt | $32.63B | $32.12B | $28.44B | $27.35B | $32.40B | $41.44B |
| Total Liabilities | $111.62B | $108.00B | $110.57B | $98.78B | $108.61B | $117.67B |
| Shareholders' Equity | $63.28B | $74.02B | $76.80B | $68.77B | $71.49B | $81.54B |
Johnson & Johnson Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $23.54B | $23.41B | $21.19B | $22.79B | $24.27B | $24.53B |
| Cash From Investing | -$20.82B | -$8.68B | -$12.37B | $878.0M | -$18.60B | -$23.59B |
| Cash From Financing | -$6.12B | -$14.05B | -$8.87B | -$15.82B | -$3.13B | -$5.54B |
| Free Cash Flow | $20.19B | $19.76B | $17.18B | $18.25B | $19.84B | $19.70B |
Figures from Johnson & Johnson's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Johnson & Johnson financials page for every line item.
Johnson & Johnson Company Profile
| Ticker | JNJ |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | New Brunswick, New Jersey |
| Incorporated in | New Jersey |
| Fiscal Year End | January 3 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000200406 |
Frequently Asked Questions
What was Johnson & Johnson's revenue in fiscal 2025?
Johnson & Johnson (JNJ) reported revenue of $94.19B for fiscal 2025.
What is Johnson & Johnson's annual revenue history?
Johnson & Johnson's annual revenue by fiscal year: 2020: $82.58B; 2021: $93.78B; 2022: $94.94B; 2023: $85.16B; 2024: $88.82B; 2025: $94.19B.
What was Johnson & Johnson's net income in fiscal 2025?
Johnson & Johnson reported net income of $26.80B for fiscal 2025.
What was Johnson & Johnson's earnings per share (EPS) in fiscal 2025?
Johnson & Johnson's diluted EPS was $11.03 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Johnson & Johnson generate in fiscal 2025?
Johnson & Johnson generated $19.70B of free cash flow in fiscal 2025.
What was Johnson & Johnson's revenue last quarter?
In its most recent reported quarter (2026 Q2), Johnson & Johnson reported revenue of $25.31B.
How much debt does Johnson & Johnson have?
Johnson & Johnson reported $41.44B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Johnson & Johnson are outstanding?
Johnson & Johnson reported a weighted average of 2.41 billion basic shares outstanding in 2026 Q2.
What is Johnson & Johnson's market cap?
Based on its latest closing price, Johnson & Johnson (JNJ) has a market capitalization of about $606.63B.
When does Johnson & Johnson's fiscal year end?
Johnson & Johnson's fiscal year end, as registered with the SEC, is January 3.
Where is Johnson & Johnson headquartered?
Johnson & Johnson lists its business address in New Brunswick, New Jersey in its SEC filings.